Carson Wealth (CWM LLC)’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.3M | Buy |
26,289
+15,786
| +150% | +$1.98M | 0.01% | 738 |
|
|
2025
Q1 | $1.16M | Sell |
10,503
-11,384
| -52% | -$1.26M | ﹤0.01% | 1051 |
|
|
2024
Q4 | $2.99M | Buy |
21,887
+14,003
| +178% | +$1.91M | 0.01% | 634 |
|
|
2024
Q3 | $908K | Buy |
7,884
+1,035
| +15% | +$119K | ﹤0.01% | 1093 |
|
|
2024
Q2 | $943K | Buy |
6,849
+2,185
| +47% | +$301K | ﹤0.01% | 930 |
|
|
2024
Q1 | $643K | Buy |
4,664
+1,762
| +61% | +$243K | ﹤0.01% | 1032 |
|
|
2023
Q4 | $382K | Buy |
2,902
+853
| +42% | +$112K | ﹤0.01% | 1161 |
|
|
2023
Q3 | $231K | Buy |
2,049
+664
| +48% | +$74.9K | ﹤0.01% | 1253 |
|
|
2023
Q2 | $131K | Buy |
1,385
+127
| +10% | +$12K | ﹤0.01% | 1429 |
|
|
2023
Q1 | $127K | Sell |
1,258
-42
| -3% | -$4.24K | ﹤0.01% | 1369 |
|
|
2022
Q4 | $155K | Buy |
1,300
+47
| +4% | +$5.6K | ﹤0.01% | 1194 |
|
|
2022
Q3 | $133K | Buy |
1,253
+245
| +24% | +$26K | ﹤0.01% | 1216 |
|
|
2022
Q2 | $98K | Buy |
1,008
+471
| +88% | +$45.8K | ﹤0.01% | 1322 |
|
|
2022
Q1 | $50K | Buy |
537
+328
| +157% | +$30.5K | ﹤0.01% | 1609 |
|
|
2021
Q4 | $18K | Buy |
+209
| New | +$18K | ﹤0.01% | 2050 |
|
|
2021
Q2 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2021
Q1 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2020
Q4 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2020
Q3 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2020
Q2 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2020
Q1 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2019
Q4 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2019
Q3 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2019
Q2 | $25K | Hold |
254
| – | – | ﹤0.01% | 1688 |
|
|
2019
Q1 | $25K | Buy |
254
+230
| +958% | +$22.6K | ﹤0.01% | 1688 |
|
|
2018
Q4 | $2K | Buy |
+24
| New | +$2K | ﹤0.01% | 1769 |
|